Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.
Identifieur interne : 000485 ( PubMed/Corpus ); précédent : 000484; suivant : 000486Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.
Auteurs : Rohit Shetty ; Arkasubhra Ghosh ; Santosh G. Honavar ; Pooja Khamar ; Swaminathan SethuSource :
- Indian journal of ophthalmology [ 1998-3689 ] ; 2020.
Abstract
A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.
DOI: 10.4103/ijo.IJO_639_20
PubMed: 32221057
Links to Exploration step
pubmed:32221057Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.</title><author><name sortKey="Shetty, Rohit" sort="Shetty, Rohit" uniqKey="Shetty R" first="Rohit" last="Shetty">Rohit Shetty</name><affiliation><nlm:affiliation>Narayana Nethralaya, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Ghosh, Arkasubhra" sort="Ghosh, Arkasubhra" uniqKey="Ghosh A" first="Arkasubhra" last="Ghosh">Arkasubhra Ghosh</name><affiliation><nlm:affiliation>GROW Research Laboratory, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Honavar, Santosh G" sort="Honavar, Santosh G" uniqKey="Honavar S" first="Santosh G" last="Honavar">Santosh G. Honavar</name><affiliation><nlm:affiliation>Centre for Sight, Hyderabad, Telangana, India.</nlm:affiliation></affiliation></author><author><name sortKey="Khamar, Pooja" sort="Khamar, Pooja" uniqKey="Khamar P" first="Pooja" last="Khamar">Pooja Khamar</name><affiliation><nlm:affiliation>Narayana Nethralaya, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Sethu, Swaminathan" sort="Sethu, Swaminathan" uniqKey="Sethu S" first="Swaminathan" last="Sethu">Swaminathan Sethu</name><affiliation><nlm:affiliation>GROW Research Laboratory, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32221057</idno><idno type="pmid">32221057</idno><idno type="doi">10.4103/ijo.IJO_639_20</idno><idno type="wicri:Area/PubMed/Corpus">000485</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000485</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.</title><author><name sortKey="Shetty, Rohit" sort="Shetty, Rohit" uniqKey="Shetty R" first="Rohit" last="Shetty">Rohit Shetty</name><affiliation><nlm:affiliation>Narayana Nethralaya, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Ghosh, Arkasubhra" sort="Ghosh, Arkasubhra" uniqKey="Ghosh A" first="Arkasubhra" last="Ghosh">Arkasubhra Ghosh</name><affiliation><nlm:affiliation>GROW Research Laboratory, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Honavar, Santosh G" sort="Honavar, Santosh G" uniqKey="Honavar S" first="Santosh G" last="Honavar">Santosh G. Honavar</name><affiliation><nlm:affiliation>Centre for Sight, Hyderabad, Telangana, India.</nlm:affiliation></affiliation></author><author><name sortKey="Khamar, Pooja" sort="Khamar, Pooja" uniqKey="Khamar P" first="Pooja" last="Khamar">Pooja Khamar</name><affiliation><nlm:affiliation>Narayana Nethralaya, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author><author><name sortKey="Sethu, Swaminathan" sort="Sethu, Swaminathan" uniqKey="Sethu S" first="Swaminathan" last="Sethu">Swaminathan Sethu</name><affiliation><nlm:affiliation>GROW Research Laboratory, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Indian journal of ophthalmology</title><idno type="eISSN">1998-3689</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32221057</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1998-3689</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Indian journal of ophthalmology</Title><ISOAbbreviation>Indian J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijo.IJO_639_20</ELocationID><Abstract><AbstractText>A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review outlines the key aspects of the pathobiology associated with the morbidity and mortality in COVID-19 patients, which includes a viral response phase and an exaggerated host response phase. The review also summarizes therapeutic agents that are currently being explored along with those with potential for consideration. The broad groups of therapeutic agents discussed include those that: (i) block viral entry to host cells, (ii) block viral replication and survival in host cells, and (iii) dampen exaggerated host immune response. The various kinds of pharmaceutical prophylactic options that may be followed to prevent COVID-19 have also been discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shetty</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Narayana Nethralaya, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Arkasubhra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GROW Research Laboratory, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honavar</LastName><ForeName>Santosh G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Centre for Sight, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khamar</LastName><ForeName>Pooja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Narayana Nethralaya, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sethu</LastName><ForeName>Swaminathan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GROW Research Laboratory, Narayana Nethralaya Foundation, Bangalore, Karnataka, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Ophthalmol</MedlineTA><NlmUniqueID>0405376</NlmUniqueID><ISSNLinking>0301-4738</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">prophylaxis</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32221057</ArticleId><ArticleId IdType="pii">281523</ArticleId><ArticleId IdType="doi">10.4103/ijo.IJO_639_20</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000485 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000485 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32221057
|texte= Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32221057" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |